Avastin (bevacizumab) / Roche - LARVOL DELTA

TroFuse-022/ENGOT-ov84/GOG-3103 Part 1: A Phase 3 Study of Sacituzumab Tirumotecan (Sac-TMT) ± Bevacizumab (Bev) Maintenance Therapy vs Standard of Care (SoC) After Second-Line (2L) Platinum-Based Doublet Chemotherapy (Chemo) for Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) (ESMO 2025) - No abstract available

Clinical • P3 data • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Targeted Therapy with Dalpiciclib in a Pediatric Patient with Anaplastic Ependymoma: A Case Study and Literature Review. (PubMed, Recent Pat Anticancer Drug Discov) - "This report represents the first use of the CDK4/6 inhibitor Dalpiciclib for the treatment of anaplastic ependymoma. The treatment was guided by insights from next-generation sequencing (NGS) analysis and has shown promising results in terms of patient survival."

Journal • Brain Cancer • Ependymoma • Oncology • Pediatrics • Solid Tumor

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

BNT314-02: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - P1/2 | N=482 | Recruiting | Sponsor: BioNTech SE | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor

Nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous NSCLC and untreated brain metastases (CA209-7WF / Break B5-BM-NSCLC / AIO-TRK-0220/ass) (ESMO 2025) - No abstract available

Clinical • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Management of Neurofibromatosis Type 2 (PubMed, No Shinkei Geka) - "In patients with preserved cochlear nerve integrity, cochlear implantation is effective, and treatment strategies should be planned with this option in mind. Clinical trials of bevacizumab for pharmacological treatment are currently ongoing in Japan, and the clinical application of anti-vascular endothelial growth factor receptor vaccine therapy is anticipated."

Journal • Review • Brain Cancer • Genetic Disorders • Neurofibromatosis • Oncology • Otorhinolaryngology • Solid Tumor • NF2

reICB: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: EuroCityClinic LLC

Checkpoint inhibition • New P2 trial • Cutaneous Melanoma • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

BELLA: A Phase 2 Study of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (ESMO 2025) - No abstract available

Clinical • P2 data • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1 trial • Oncology

ICON8B: GCIG Phase III Randomised Trial Comparing First-line Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy + Bevacizumab In High-Risk Stage III-IV Epithelial Ovarian Cancer (EOC): Final Overall Survival (OS) Analysis (ESMO 2025) - No abstract available

Clinical • P3 data • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Longitudinal ctDNA Profiling in HER2-Altered NSCLC Treated With HER2 Adc: Preliminary Results From the RESOLUTION Trial (IASLC-WCLC 2025) - "A total of 28 eligible patients will receive disitamab vedotin (2.0 mg/kg), tislelizumab (200 mg), and bevacizumab (7.5 mg/kg), all administered intravenously every 3 weeks, until disease progression or unacceptable toxicity. The first-stage interim analysis revealed acceptable efficacy to support proceeding to the further stage. Longitudinal ctDNA analysis enabled dynamic monitoring of tumor burden and early detection of disease progression, underscoring its potential as a non-invasive tool for real-time treatment response assessment."

Circulating tumor DNA • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • HER-2 • TP53

Molecular Pathogenesis, Genetic Profiles, and Therapeutic Strategies for NF2-Related Schwannomatosis (PubMed, No Shinkei Geka) - "Targeted therapies-including bevacizumab, brigatinib, and vascular endothelial growth factor -A vaccines-have shown promise, particularly in refractory cases. Although routine intensive surveillance is not universally required, early genetic screening and long-term follow-ups may benefit select individuals. The comprehensive integration of genetic, pathological, and immunological data is essential for advancing personalized treatment strategies for NF2-SWN."

Journal • Review • Brain Cancer • CNS Tumor • Genetic Disorders • Meningioma • Neurofibromatosis • Oncology • Solid Tumor • NF2

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer. (PubMed, Am J Cancer Res) - "Trifluridine/tipiracil (FTD-TPI) plus bevacizumab is an established option for refractory metastatic colorectal cancer (mCRC). After adjustment for age, sex, tumour sidedness and time from metastatic diagnosis to FTD-TPI, anti-EGFR therapy remained the only independent predictor of response (posterior OR ≈ 7; 95% credible interval 1.1-66). These data suggest that FTD-TPI plus anti-EGFR rechallenge provides greater tumour shrinkage and at least comparable survival versus FTD-TPI plus anti-VEGF in heavily pre-treated, wild-type mCRC, supporting further prospective evaluation."

Journal • Colorectal Cancer • Oncology • Solid Tumor • BRAF • EGFR • RAS

Toripalimab Plus Bevacizumab and Chemoradiotherapy as Treatment in Patients With Advanced Melanoma: The IRAC Phase 2 Nonrandomized Clinical Trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Melanoma • Oncology • Solid Tumor

Sex and Histology Related Profile of Gut Microbiota (GM) in Pleural Mesothelioma (PM): Preliminary Results of a Prospective Observational Study (IASLC-WCLC 2025) - "A single prospective experience highlights the positive prognostic value of Prevotella and Eubacterium ventriosum and the negative prognostic value of Erysipelatoclostridium in a small cohort of patients treated with atezolizumab and bevacizumab as salvage therapy...Pts were mostly male (41/50), median age was 72 years (IQR 65-76), were treated with pemetrexed and platinum derivatives chemotherapy (34/50), had an epithelioid histology (34/50)...Conclusions : These preliminary results highlight a significant difference in beta diversity as well as species specific GM composition in PM patients, related to histology and sex. Further correlative analyses on the impact of GM composition, its modification during treatment and its association with response and survival are planned."

Clinical • Gut Microbiota • Observational data • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

LEAF-02: Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab (clinicaltrials.gov) - P2 | N=141 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial. (PubMed, Thorac Cancer) - "Afatinib combined with bevacizumab is well tolerated with moderate efficacy among patients with NSCLC, which might be a prospective strategy for patients with uncommon EGFR mutations and pleural metastasis."

Journal • P2 data • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR

FTM-JSNO-03:A phase II study of fecal microbiota transplantation (FMT) plus QL1706 plus Bevacizumab plus XELOX for first-line (1L) treatment of advanced Microsatellite-stable (MSS) type colon cancer with liver metastasis (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor

Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-related Unresectable Hepatocellular Carcinoma. (PubMed, Oncology) - "Although SVR was not independently associated with better survival, patients with SVR had preserved liver function and experienced fewer adverse events. These factors may indirectly support improved tolerability and therapeutic options during Atez/Bev therapy for HCV-related uHCC."

Journal • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Failure • Oncology • Solid Tumor

Cost-Effectiveness of Treatments for Diabetic Macular Edema: Simulated Bevacizumab-First Step Therapy Versus Real-World Practice. (PubMed, J Vitreoretin Dis) - " Compared with real-world treatment, protocol AC bevacizumab-first treatment for DME was generally not cost-saving. Although better vision outcomes were achieved with bevacizumab-first, the protocol was generally not cost-effective due to greater treatment burdens."

HEOR • Journal • Real-world evidence • Diabetic Macular Edema • Ophthalmology

Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab. (PubMed, Liver Cancer) - "Atezolizumab-bevacizumab (Atezo-Bev) has become the standard first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). Second-line regorafenib was effective for treating uHCC progression after first-line Atezo-Bev. The efficacy and safety outcomes from our study were consistent with those observed in the pivotal phase 3 RESORCE trial, which included sorafenib-tolerant/-progressed patients."

Journal • P2 data • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor • Thrombocytopenia

Recurrent Respiratory Papillomatosis: Updates on Diagnosis and Management (AAO-HNSF 2025) - "Panelists include otolaryngologists who have family members with the disease and who have spent their careers investigating novel therapeutic modalities, including cidofovir, intravenous bevacizumab and anti-tumor vaccines. They will also provide perspectives on treating both adults and children with this challenging disease.OUTCOME OBJECTIVE 1: Explain treatment modalities for RPP, including novel therapies such as intravenous bevacizumab and therapeutic vaccinesOUTCOME OBJECTIVE 2: Recognize the stigma that can accompany diagnosis and treatment of RRP and sensitively counsel patientsOUTCOME OBJECTIVE 3: Navigate barriers to access and care for patientsBACKGROUND STATEMENT: Review of treatment options for RRP and HPV vaccination given recent advances in the field, especially as antitumor vaccines may be FDA approved soonComprehensive Otolaryngology Track Statement :"

CNS Disorders • Depression • Otorhinolaryngology • Pediatrics • Psychiatry • Pulmonary Disease

A 2-Year Follow-Up of Zanidatamab (Zani) + mFOLFOX6 ± Bevacizumab (Bev) in First-Line (1L) Treatment of Patients (Pts) With Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Advanced/Metastatic Colorectal Cancer (mCRC) (ESMO 2025) - No abstract available

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • HER-2

Long-Term Control of Leptomeningeal Disease in NSCLC With EGFR Mutations: A Case Series (IASLC-WCLC 2025) - "She underwent craniospinal proton therapy and four cycles of carboplatin/ pemetrexed/ bevacizumab with osimertinib...She received four cycles of carboplatin/etoposide plus osimertinib, maintaining stable CNS disease...Conclusions : These cases illustrate that NSCLC patients with LMD and actionable mutations can achieve prolonged responses to targeted therapies, challenging the historically grim prognosis of LMD. Early detection and initiation of targeted agents, in conjunction with close radiation oncology support, may be crucial in extending survival."

Clinical • Chronic Cough • CNS Disorders • Cough • Lung Cancer • Musculoskeletal Pain • Non Small Cell Lung Cancer • Respiratory Diseases • Solid Tumor • CHEK2 • DLL3 • EGFR • MAP2K4 • RB1 • TP53

First-line (1L) panitumumab (PAN) vs bevacizumab (BEV) in patients (pts) with mucinous histology in RAS wild-type (WT) metastatic colorectal cancer (mCRC): Findings from the PARADIGM trial (ESMO 2025) - No abstract available

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor • RAS